Double-contrast MRI (DC-MRI) in the study of the cirrhotic liver: Utility of administering Gd-DTPA as a complement to examinations in which SPIO liver uptake and distribution alterations (SPIO-LUDA) are present and in the identification and characterisation of focal lesions;RM epatica a doppio contrasto (RM-DC) nello studio del fegato cirrotico: Utilità della somministrazione di Gd-DTPA come completamento di esami in cui siano presenti alterazioni di captazione e distribuzione epatiche (ACDE) del MdC SPIO e nell'identificazione e caratterizzazione delle lesioni focali

Radiologia Medica

Volumn 111, Issue 8, 2006, Pages 1087-1102

  Macarini, Luca ^a,c   Marini, S ^a   Milillo, P ^a   Vinci, R ^a   Ettorre, G C ^b  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c NONE   (Italy)

Author keywords

Cirrhosis; Contrast; Liver; Medium; MR

Indexed keywords

SUPERPARAMAGNETIC IRON OXIDE;

ARTICLE; BLOOD TESTIS BARRIER; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DOUBLE CONTRAST RADIOGRAPHY; HUMAN; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER FUNCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; URINALYSIS;

CONTRAST MEDIA; FOLLOW-UP STUDIES; GADOLINIUM DTPA; HUMANS; IRON; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING; OXIDES; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 33846010752     PISSN: 00338362     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11547-006-0107-3     Document Type: Article

References (46)

1. Denys A, Arrive L, Servois V et al (1994) Hepatic tumors: detection and characterization a 1-T MR imaging enhanced with AMI-25. Radiology 193: 665-669
2. Grangier C, Tourniaire J, Mentha G et al (1994) Enhancement of liver hemangiomas on T1-weighted MR SE imaging by superparamagnetic iron oxide particles. JCAT 18: 888-896
3. Hagspiel KD, Neidl KFW, Eichenberger AC et al (1995) Detection of liver metastases: comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5T with dynamic CT, intraoperative US and percutaneous US. Radiology 196: 471-478
4. Oudkerk M, van den Henvel AG, Wielopolski PA et al (1997) Hepatic lesions: detection with ferumoxide-enhanced T1-wieghted MR imaging. Radiology 203: 449-456
5. Seneterre E, Taourel P, Bouvier Y et al (1996) Detection of hepatic metastasis: ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial-portography. Radiology 200: 785-792
6. Stark DD, Weissleder R, Elizondo G et al (1988) Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology 162: 297-301
7. Van Beers B, La Crosse M, Jamart J et al (1997) Detection and segmental location of malignant hepatic tumors: comparison of ferumoxides-enhanced gradient-eco and T2-weighted spin-echo MR imaging. AJR 168:713-717
8. Van Gansbeke D, Metens TM, Matos C et al (1997) Effects of AMI-25 on liver vessels and tumors on T1-weighted Turbo-Field-Echo images: implications for tumor characterization. JMRI 7: 482-489
9. Sugihara S, Suto Y, Kamba M, Ogawa T (2001) Comparison of various techniques of iron oxide-enhanced breath-hold MR imaging of hepatocellular carcinoma. Clin Imaging 25:104-109
10. Suto Y, Kodama F (1996) Usefulness of iron colloid-enhanced MRI in differentiating experimental hepatocellular carcinoma from hyperplastic nodules in rats: analysis by microautoradiography. BJR 69:1139-1144
11. Yamamoto H, Yamashita Y, Yoshimatsu S et al (1995) Hepatocellular carcinoma in cirrhotic livers: detection with unenhanced and iron-oxide enhanced MR imaging. Radiology 195: 106-112
12. Pauleit D, Textor J, Bachmann R et al (2002) Hepatocellular carcinoma: detection with gadolinium and ferumoxides-enhanced MR imaging of the liver. Radiology 222: 73-80
13. Peterson M, Baron R, Muratami T (1996) Hepatic malignancies: usefulness of acquisition of multiple arterial and portal venous phase images at dynamic gadolinium-enhanced MR imaging Radiology 201: 337-345
14. Rode A, Bancel B, Douek P et al (2001) Small nodule detection in cirrhotic livers: evaluation with US, spiral CT and MRI and correlation with pathologic examination of explanted liver. JCAT 25: 327-336
15. Tang Y, Yamashita Y, Arakawa A et al (1999) Detection of hepatocellular carcinoma arising in cirrhotic liver: comparison of gadolinium and ferumoxides-enhanced MR imaging. AJR 172: 1547-1554
16. Simon G, Link TM, Woortler K et al (2005) Detection of hepatocellular carcinoma: comparison of Gd-DTPA-and ferumoxides-enhanced MR imaging. Eur Radiol 15: 895-903
17. Vogl TJ, Hammerstingl R, Schwarz W et al (1996) Superparamagnetic iron oxide-enhanced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesions. Radiology 198: 881-887
18. Kwak HS, Lee JM, Kim CS (2004) Preoperative detection of hepatocellular carcinoma: comparison of combined contrast-enhanced MR imaging and combined CT during arterial portography and CT hepatic arteriography. Eur Radiol 14: 447-457
19. Nakamura H, Ito N, Nokate F et al (2000) Tumor-detecting capacity and clinical usefulness of SPIO-MRI in patients with hepatocellular carcinoma. J Gastroenterol 35: 849-855
20. Semelka RC, Lee JKT, Norawattanakul S et al (1998) Sequential use of ferumoxide particles and Gadolinium chelate for the evaluation of focal liver lesions on MRI. JMRI 8: 670
21. Suto Y, Shimatani Y (1995) Dual contrast magnetic resonance imaging with combined used of positive and negative contrast agent in human hepatocellular carcinoma. BJR 68: 116-120
22. Ward J, Guthrie JA, Scott DJ et al (2000) Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis. Radiology 216:154-162
23. Arbab AS, Ichikawa T, Araki T et al (2000) Detection of hepatocellular carcinoma and its metastases with various pulse sequences using superparamagnetic iron oxide (SHU-555-A). Abdom Imaging 25: 151-158
24. Clement O, Frija G, Chambon C et al (1991) Liver tumors in cirrhosis: experimental study with SPIO-enhanced MR imaging. Radiology 180: 31-36
25. Elizondo G, Weissleder R, Stark DD (1990) Hepatic cirrhosis and hepatitis: MR imaging enhanced with superparamagnetic iron oxide. Radiology 174: 797-801
26. Hundt W, Petsch R, Helmberger T et al (2000) Signal changes in liver and spleen after Endorem administration in patients with and without liver cirrhosis. Eur Radiol 10: 409-416
27. Lim JH, Choi D, Cho SK et al (2001) Conspicuity of hepatocellular nodular lesion in cirrhotic liver at ferumoxides-enhanced MR imaging: importance of Kupffer cell number. Radiology 220: 669-676
28. Matsuo M, Kanematsu M, Kondo H et al (2001) Confluent hepatic fibrosis in cirrhosis: ferumoxides-enhanced MR imaging findings. Abdom Imaging 26:146-148
29. Mori K, Yoshioka H, Itai Y et al (2000) Arterioportal shunts in cirrhotic patients: evaluation of the difference between tumorous and nontumorous arterioportal shunts on MR imaging with superparamagnetic iron oxide. AJR 175:1659-1664
30. Macarini L, Marini S, Murrone M, Ettorre G.C. (2004) Alterazioni della captazione e della distribuzione epatiche dei mezzi di contrasto superparamagnetici organo-specifici per Risonanza Magnetica. Rilievo clinico e classificazione sulla base del meccanismo patogenetico. Radiol Med 108: 159-171
31. Lencioni R, Bartolozzi C, Caramella D, Di Coscio G (1993) Managment of adenomatous hyperplastic nodules in cirrhotic liver disease. US follow-up or percutaneous alcohol ablation? Abdom Imaging 18: 50-55
32. Mazzaferro V, Regalia E, Doci R et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334: 693-699
33. Halavaara J, Tervahartiala P, Isoniemi H et al (2002) Efficacy of sequential use of superparamagnetic iron oxide and gadolinium in liver MR imaging. Acta Radiologica 43: 180-185
34. Ferrucci JT, Stark DD (1990) Iron oxide-enhanced MR imaging of the liver and spleen: review of the first 5 years. AJR 155: 943-950
35. Petersein J, Saini S, Weissleder R (1996) Liver II: iron oxide-based reticuloendothelial contrast agents for imaging. Magnetic Reson Imaging Clin N Am 4: 53-60
36. Ros PR, Freeny PC, Harms SE et al (1995) Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 196: 481-488
37. Shimizu A, Ito K, Koike S et al (2003) Cirrhosis or chronic hepatitis: evaluation of small (<=2-cm) early-enhancing hepatic lesions with serial contrast-enhanced dynamic MR imaging. Radiology 226: 550-555
38. Lwakatare F, Yamashita Y, Nakayama M et al (2001) SPIO-enhanced MR imaging of focal fatty liver lesions. Abdom Imaging 26: 157-160
39. Ohtomo K, Baron RL, Dodd GD 3rd et al (1993) Confluent hepatic fibrosis in advanced cirrhosis: evaluation with MR imaging. Radiology 189: 871-874
40. Scharf K, Hoffmann V, Lehnert T et al (1998) Pseudolesions at T1-weighted gradient-echo imaging after administration of superparamagnetic iron oxide: comparison with portal perfusion abnormalities at CT during arterial portography. Radiology 207: 67-72
41. Mori K, Yoshioka H, Ahmadi T et al (2000) Early radiation effects on the liver demonstrated on superparamagnetic iron oxide enhanced T1-weighted MRI. J Comput Assist Tomogr 24: 648-651
42. Weissleder R, Saini S, Stark DD et al (1988) Dual contrast MR imaging of liver cancer in rats. AJR 150: 561-566
43. Earls JP, Theise N, Wein reb IC et al (1996) Dysplastic nodules and hepatocellular carcinoma: thin-section MR imaging of explanted cirrhotic liver with pathologic correlation. Radiology 201:207-214
44. Dao T, Mathieu D, Nguyen-tan T et al (1991) Value of MR imaging in evaluating focal fatty infiltration of the liver: preliminary study. Radiographics 11: 1003-1012
45. Matsui O, Kodoya M, Kameyama T et al (1991) Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 178: 493-497
46. Weissleder R, Stark DD, Engelstad BL et al (1989) Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR 152: 167-173